Overview
Fievel Lim is an intellectual property attorney who focuses on patent litigation. Much of his work involves providing counsel to pharmaceutical and biotechnology companies involved in Hatch-Waxman litigation. He advises on matters in litigation at district courts, inter partes reviews (IPRs) at the Patent Trial and Appeal Board, and provides freedom-to-operate analyses.
Previously, he conducted COVID-19 diagnostic research, optimized qPCR protocols for COVID-19 detection, designed qPCR primers targeting COVID-19, and tested automated COVID-19 medical devices as a research assistant at a Canadian-based biotech firm. He also drafted patent application materials for new engineering designs.
- New York
- J.D., University of Toronto
- M.S., University of Toronto, Laboratory Medicine and Pathobiology
- Durham College, Pharmaceutical and Food Science Technology
- B.S., University of Toronto, Laboratory Medicine and Pathobiology